1. Home
  2. DNUT vs BEAM Comparison

DNUT vs BEAM Comparison

Compare DNUT & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Krispy Kreme Inc.

DNUT

Krispy Kreme Inc.

HOLD

Current Price

$4.43

Market Cap

734.9M

ML Signal

HOLD

Logo Beam Therapeutics Inc.

BEAM

Beam Therapeutics Inc.

HOLD

Current Price

$26.84

Market Cap

2.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DNUT
BEAM
Founded
1937
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Food Chains
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
734.9M
2.3B
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
DNUT
BEAM
Price
$4.43
$26.84
Analyst Decision
Buy
Strong Buy
Analyst Count
6
12
Target Price
$6.22
$48.09
AVG Volume (30 Days)
3.4M
2.0M
Earning Date
11-06-2025
11-04-2025
Dividend Yield
1.59%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,534,272,000.00
$55,701,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$0.77
$26.52
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.50
$13.53
52 Week High
$10.40
$35.25

Technical Indicators

Market Signals
Indicator
DNUT
BEAM
Relative Strength Index (RSI) 58.26 57.34
Support Level $4.35 $25.86
Resistance Level $4.75 $28.10
Average True Range (ATR) 0.20 1.56
MACD 0.02 0.19
Stochastic Oscillator 59.62 63.28

Price Performance

Historical Comparison
DNUT
BEAM

About DNUT Krispy Kreme Inc.

Krispy Kreme Inc is a sweet treat brand company. The company's Original Glazed doughnut is recognized for its hot-off-the-line, melt-in-your-mouth experience. It operates through its network of fresh Doughnut Shops, partnerships with retailers, and a growing e-commerce and delivery business. The company conducts its business through the following three reported segments: U.S., which includes all operations in the United States; International, which includes operations in the U.K., Ireland, Australia, New Zealand, Canada, Japan, and Mexico; and Market Development, which includes franchise operations across the globe. It derives maximum revenue from the U.S. segment.

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

Share on Social Networks: